Heterogeneity in melanoma

Cancer Treatment and Research

Volumn 167, Issue , 2016, Pages 1-15

  Shannan, Batool ^a   Perego, Michela ^a   Somasundaram, Rajasekharan ^a   Herlyn, Meenhard ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Heterogeneity; Melanoma; Therapy

Indexed keywords

CANCER RESISTANCE; CLINICAL FEATURE; CPG ISLAND; GAIN OF FUNCTION MUTATION; GENETIC HETEROGENEITY; HUMAN; LOSS OF FUNCTION MUTATION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; CLASSIFICATION; GENETICS; PATHOLOGY;

TUMOR MARKER;

BIOMARKERS, TUMOR; HUMANS; MELANOMA;

EID: 84948744587     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-319-22539-5_1     Document Type: Chapter

References (71)

1. Anderson K, Lutz C, van Delft FW et al (2011) Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469:356–361
2. Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL (2011) TGFbeta/TNF(alpha)- mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res 71:4707–4719
3. Bailey CM, Morrison JA, Kulesa PM (2012) Melanoma revives an embryonic migration program to promote plasticity and invasion. Pigm Cell Melanoma Res 25:573–583
4. Bastian BC (2014) The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Ann Rev Pathol 9:239–271
5. Bittner M, Meltzer P, Chen Y et al (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536–540
6. Boiko AD, Razorenova OV, van de Rijn M et al (2010) Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466:133–137
7. Boonyaratanakornkit JB, Yue L, Strachan LR et al (2010) Selection of tumorigenic melanoma cells using ALDH. J Invest Dermatol 130:2799–2808
8. Borrull A, Ghislin S, Deshayes F, Lauriol J, Alcaide-Loridan C, Middendorp S (2012) Nanog and Oct4 overexpression increases motility and transmigration of melanoma cells. J Cancer Res Clin Oncol 138:1145–1154
9. Campbell PJ, Yachida S, Mudie LJ et al (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467:1109–1113
10. Cheli Y, Giuliano S, Fenouille N et al (2012) Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene 31:2461–2470
11. Civenni G, Walter A, Kobert N et al (2011) Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res 71:3098–3109
12. Ding L, Ellis MJ, Li S et al (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464:999–1005
13. Ding L, Ley TJ, Larson DE et al (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481:506–510
14. Fang D, Nguyen TK, Leishear K et al (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65:9328–9337
15. Frank NY, Schatton T, Kim S et al (2011) VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res 71:1474–1485
16. Gerlinger M, Horswell S, Larkin J et al (2014) Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 46:225–233
17. Ghislin S, Deshayes F, Lauriol J et al (2012) Plasticity of melanoma cells induced by neural cell crest conditions and three-dimensional growth. Melanoma Res 22:184–194
18. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445:851–857
19. Holzel M, Bovier A, Tuting T (2013) Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 13:365–376
20. Jandl T, Revskaya E, Jiang Z et al (2013) Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy. Nucl Med Biol 40:177–181
21. Keats JJ, Chesi M, Egan JB et al (2012) Clonal competition with alternating dominance in multiple myeloma. Blood 120:1067–1076
22. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR (2007) Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20:102–107
23. Knutson KL, Lu H, Stone B et al (2006) Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol 177:1526–1533
24. Koefinger P, Wels C, Joshi S et al (2011) The cadherin switch in melanoma instigated by HGF is mediated through epithelial-mesenchymal transition regulators. Pigm Cell Melanoma Res 24:382–385
25. Krepler C, Chunduru SK, Halloran MB et al (2013) The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res 19:1784–1794
26. Kulbe H, Chakravarty P, Leinster DA et al (2012) A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res 72:66–75
27. Landsberg J, Kohlmeyer J, Renn M et al (2012) Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490:412–416
28. Li L, Fukunaga-Kalabis M, Yu H et al (2010) Human dermal stem cells differentiate into functional epidermal melanocytes. J Cell Sci 123:853–860
29. Lin J, Goto Y, Murata H et al (2011) Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer 104:464–468
30. Long GV, Wilmott JS, Haydu LE et al (2013) Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. Pigm Cell Melanoma Res 26:499–508
31. Luo Y, Dallaglio K, Chen Y et al (2012) ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells 30:2100–2113
32. Maley CC, Galipeau PC, Finley JC et al (2006) Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 38:468–473
33. Mar VJ, Wong SQ, Li J et al (2013) BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res 19:4589–4598
34. Monzani E, Facchetti F, Galmozzi E et al (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43:935–946
35. Mroz EA, Tward AD, Pickering CR, Myers JN, Ferris RL, Rocco JW (2013) High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer 119:3034–3042
36. Nazarian R, Shi H, Wang Q et al (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973–977
37. Nickel GC, Barnholtz-Sloan J, Gould MP et al (2012) Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence. PLoS ONE 7:e35262
38. O’Connell MP, Marchbank K, Webster MR et al (2013) Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov 3:1378–1393
39. O’Leary RE, Diehl J, Levins PC (2014) Update on tanning: more risks, fewer benefits. J Am Acad Dermatol 70:562–568
40. Piccirillo SG, Combi R, Cajola L et al (2009) Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene 28:1807–1811
41. Pinc A, Somasundaram R, Wagner C et al (2012) Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther 20:1056–1062
42. Pinnix CC, Lee JT, Liu ZJ et al (2009) Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res 69:5312–5320
43. Prasmickaite L, Engesaeter BØ, Skrbo N et al (2010) Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS ONE 5:e10731
44. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593–598
45. Quintana E, Shackleton M, Foster HR et al (2010) Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18:510–523
46. Roesch A, Fukunaga-Kalabis M, Schmidt EC et al (2010) A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141:583–594
47. Roesch A, Vultur A, Bogeski I et al (2013) Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 23:811–825
48. Schadendorf D, Fisher DE, Garbe C et al (2015) Melanoma. Nature Rev Dis Primers 1:1–20
49. Schatton T, Schutte U, Frank NY et al (2010) Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res 70:697–708
50. Schatton T, Murphy GF, Frank NY et al (2008) Identification of cells initiating human melanomas. Nature 451:345–349
51. Schmidt P, Kopecky C, Hombach A, Zigrino P, Mauch C, Abken H (2011) Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci USA 108:2474–2479
52. Schwitalla S, Fingerle AA, Cammareri P et al (2013) Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152:25–38
53. Sensi M, Nicolini G, Petti C et al (2006) Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25:3357–3364
54. Shi H, Hugo W, Kong X et al (2014) Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4:80–93
55. Slingluff CL Jr, Colella TA, Thompson L et al (2000) Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother 48:661–672
56. Sottoriva A, Spiteri I, Piccirillo SG et al (2013) Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 110:4009–4014
57. Straussman R, Morikawa T, Shee K et al (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500–504
58. Sztiller-Sikorska M, Koprowska K, Jakubowska J et al (2012) Sphere formation and self-renewal capacity of melanoma cells is affected by the microenvironment. Melanoma Res 22:215–224
59. Terzian T, Torchia EC, Dai D et al (2010) P53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigm Cell Melanoma Res 23:781–794
60. Tsao H, Goel V, Wu H, Yang G, Haluska FG (2004) Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122:337–341
61. Turke AB, Zejnullahu K, Wu YL et al (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17:77–88
62. Vitale M (2013) Intratumor BRAFV600E heterogeneity and kinase inhibitors in the treatment of thyroid cancer: a call for participation. Thyroid 23:517–519
63. Wan PT, Garnett MJ, Roe SM et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–867
64. Wilmott JS, Tembe V, Howle JR et al (2012) Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Mol Cancer Ther 11:2704–2708
65. Wilson TR, Fridlyand J, Yan Y et al (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487:505–509
66. Yachida S, Jones S, Bozic I et al (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114–1117
67. Yancovitz M, Litterman A, Yoon J et al (2012) Intra- and inter-tumor heterogeneity of BRAF (V600E)mutations in primary and metastatic melanoma. PLoS ONE 7:e29336
68. Yu H, Kumar SM, Kossenkov AV, Showe L, Xu X (2010) Stem cells with neural crest characteristics derived from the bulge region of cultured human hair follicles. J Invest Dermatol 130:1227–1236
69. Yue L, Huang ZM, Fong S et al (2015) Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma. Melanoma Res 25:138–148
70. Zabierowski SE, Fukunaga-Kalabis M, Li L, Herlyn M (2011) Dermis-derived stem cells: a source of epidermal melanocytes and melanoma? Pigm Cell Melanoma Res 24:422–429
71. Zhang M, Qureshi AA, Geller AC, Frazier L, Hunter DJ, Han J (2012) Use of tanning beds and incidence of skin cancer. J Clin Oncol 30:1588–1593